🇪🇺 Proactive TDM-based dosing of ixekizumab in European Union

EMA authorised Proactive TDM-based dosing of ixekizumab on 25 April 2016

Marketing authorisation

EMA — authorised 25 April 2016

  • Application: EMEA/H/C/003943
  • Marketing authorisation holder: Eli Lilly and Company (Ireland) Limited
  • Local brand name: Taltz
  • Indication: Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Paediatric plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more d
  • Status: approved

Read official source →

Proactive TDM-based dosing of ixekizumab in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Proactive TDM-based dosing of ixekizumab approved in European Union?

Yes. EMA authorised it on 25 April 2016.

Who is the marketing authorisation holder for Proactive TDM-based dosing of ixekizumab in European Union?

Eli Lilly and Company (Ireland) Limited holds the EU marketing authorisation.